Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | TOP2A | P11388 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20788033 | 1.00 | ALDH1A1 (0.60) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL20788019 | 0.92 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL20788020 | 0.92 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL5135534 | 0.92 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL5135532 | 0.92 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL27882845 | 0.90 | KMT2A (0.51) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL3616763 | 0.90 | KDM4E (0.66) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL3616760 | 0.90 | KDM4E (0.66) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL28429658 | 0.84 | KMT2A (0.55) | ALDH1A1SMN1; SMN2TOP2AKMT2AMEN1 | |
| SCHEMBL28633075 | 0.84 | AKR1C3 (0.58) | ALDH1A1KDM4ESMN1; SMN2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385013-B2 | Micro/nano materials, products obtained by covalently modifying surface of micro/nano materials with hydrophilic materials, and method for making same | CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-20 | — | — | US | disclosed |
| EP-3470443-A1 | MICRO/NANOMATERIAL, PRODUCT THEREOF WITH SURFACE COVALENTLY MODIFIED WITH HYDROPHILIC MATERIAL, AND MANUFACTURING METHOD | Chongqing Bolanying (BLY) Biotechnology Co., Ltd., China (CN) | 2019-04-17 | — | — | EP | disclosed |
| US-20190077746-A1 | MICRO/NANO MATERIALS, PRODUCTS OBTAINED BY COVALENTLY MODIFYING SURFACE OF MICRO/NANO MATERIALS WITH HYDROPHILIC MATERIALS, AND METHOD FOR MAKING SAME | CHONGQING BOLANYING (BLY) BIOTECHNOLOGY CO., LTD. (CN) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077746-A1 | MICRO/NANO MATERIALS, PRODUCTS OBTAINED BY COVALENTLY MODIFYING SURFACE OF MICRO/NANO MATERIALS WITH HYDROPHILIC MATERIALS, AND METHOD FOR MAKING SAME | PHOSPHO1, PTMS, PAM | ALDH1A1 1407/4885KDM4E 1621/4885SMN1; SMN2 4658/4885 |
| US-10385013-B2 | Micro/nano materials, products obtained by covalently modifying surface of micro/nano materials with hydrophilic materials, and method for making same | PHOSPHO1, PTMS, PAM | ALDH1A1 1407/4885KDM4E 1621/4885SMN1; SMN2 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.